There are 2949 resources available
535MO - BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Presenter: Juan Martin Liberal
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
536MO - A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours
Presenter: John Sarantopoulos
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA89 - A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
Presenter: Yansong Lin
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1914MO - Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912
Presenter: Eric Sherman
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1158MO - Metabolomic profile of advanced neuroendocrine cancer patients
Presenter: Beatriz Soldevilla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1159MO - Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE)
Presenter: Paula Jimenez Fonseca
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1166MO - Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas
Presenter: Constance Lamy
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1161MO - Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
Presenter: Piero Ferolla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1162MO - Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
Presenter: Marianne Pavel
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA85 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
Presenter: Benjamin Besse
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast